Peptide oral strip COAs: HPLC purity, assay and actual content

Read what the percentage actually measures

Chromatographic area purity describes a detector response within a defined separation and integration procedure. The reported proportion depends on which peaks are detected, included and resolved. Water, salts and other components do not necessarily contribute to that result in the same way as the peptide peaks. A mass-based assay instead quantifies a defined analyte against an appropriate standard using a stated calculation. Neither result replaces identity testing. An apparently clean main peak can coexist with uncertainty about the material basis or an unresolved interference. ICH Q2(R2) distinguishes analytical purposes and asks for procedures that are fit for their intended use. [1] In a purchasing review, ask what the result means before deciding whether the number is high enough. The answer should identify the method and its scope, rather than repeat the purity claim from a product listing.

Reference-standard content needs its own definition

An assay result inherits the basis of its reference standard and calculation. EDQM training on pharmacopoeial reference standards describes content assignment using a mass-balance approach that considers water, counterions and related peptides, with supporting characterization. [2] That example explains why a supplier should provide more than the main-peak percentage. It does not mean that a commercial peptide ingredient is an EDQM reference standard or meets a pharmacopoeial monograph. Request the identity of the standard used, its applicable assigned value and the document that supports that value. Check whether the final result is expressed for the supplied chemical form or for a defined peptide equivalent. When two laboratories report different percentages, first compare these definitions. A disagreement about units or correction basis can look like a batch-quality difference even when the laboratories are measuring the same material.

• Reference-standard identity, lot and intended analytical use.
• Assigned content or potency value and its basis.
• Applicable leaflet or certificate version.
• Result calculation, including any water or chemical-form correction.

An as-received assay supports a specific mass calculation

Suppose an ingredient has a documented assay of 84% by mass as received for a clearly defined analyte. A hypothetical 100 mg portion then corresponds to 84 mg of that analyte on the same basis. This says nothing about what an unrelated HPLC purity result would have been. Do not multiply the 84 mg again by a chromatographic area percentage unless the validated calculation explicitly requires that operation. A second correction can count the same issue twice. The distinction matters when a formula sheet moves from powder weight to an intended content declaration. Keep the supplied-material amount and the calculated analyte amount in separate columns. This example is arithmetic only; it is not a certificate, a tested ingredient, a finished-film result or a suggested human serving. Actual use needs the applicable batch documents and market review.

• Use a mass-based factor only when its basis matches the calculation.
• Do not infer an assay from an area-purity statement.
• Avoid duplicate corrections for water, purity or chemical form.

A raw-material COA does not measure the finished strip

The ingredient certificate describes the material and tests identified on that document. After the ingredient enters a film matrix, the finished unit has its own sampling and analytical questions. The polymer system can affect sample preparation, and a content result for one pooled extract can conceal differences among individual strips. A finished-film assay therefore needs a defined unit, a suitable method and a sampling plan connected to the batch. Ask whether the reported value is per strip, per gram of film or relative to a nominal claim. Confirm which formula and packaging version the result covers. ICH Q14 discusses analytical procedure development across its lifecycle; its principles help frame these questions, without establishing that a particular film method has been developed or validated. [3] A purchaser still needs evidence for the actual product under discussion.

• Raw-material batch and finished-film batch identifiers.
• Formula version and the material basis used in the calculation.
• Individual-unit or pooled sampling, stated explicitly.
• Analytical method version and result units.

Resolve reporting differences before accepting a comparison

Two certificates are comparable only when their measurement definitions are compatible. Start with identity and chemical form, then compare assay basis, reference-standard assignment and reporting units. Check the sampling date and whether the document applies to the supplied lot. A headline purity value may be unsuitable for deciding which offer provides more of the defined analyte per unit mass. Price comparisons made on that assumption can also be misleading, although commercial decisions require additional information beyond assay. Where the basis is missing, request clarification instead of estimating a correction from another supplier's certificate. The quality agreement should name the accepted specification and the method used to resolve disagreements. Any requirement for independent testing should identify who selects the laboratory, what sample it receives and which analytical question it is expected to answer before a result is commissioned.

• Compare matching identity and result bases.
• Request missing definitions from the issuing laboratory.
• Agree the method and specification used for acceptance.
• Keep independent-testing scope separate from a generic purity promise.